Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial

Neurology

Volumn 83, Issue 4, 2014, Pages 328-335

  Kaufmann, Horacio ^a   Freeman, Roy ^b   Biaggioni, Italo ^c   Low, Phillip ^d   Pedder, Simon ^e   Hewitt, L Arthur ^e   Mauney, Joe ^f   Feirtag, Michael ^g   Mathias, Christopher J ^h,i  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e LUNDBECK RESEARCH USA   (United States)

^f Chiltern   (United States)

^g Curry Rockefeller Group   (United States)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AUTONOMIC AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD PRESSURE; DIZZINESS; DOUBLE-BLIND METHOD; DROXIDOPA; FEMALE; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE; POSTURE; PURE AUTONOMIC FAILURE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84905870171     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000615     Document Type: Article

References (31)

1. Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res 1996;6:125-126.
2. Freeman R. Clinical practice: neurogenic orthostatic hypotension. N Engl J Med 2008;358:615-624.
3. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21:69-72.
4. Mann S, Altman DG, Raftery EB, Bannister R. Circadian variation of blood pressure in autonomic failure. Circulation 1983;68:477-483.
5. Okamoto LE, Gamboa A, Shibao C, et al. Nocturnal blood pressure dipping in the hypertension of autonomic failure. Hypertension 2009;53:363-369.
6. Voichanski S, Grossman C, Leibowitz A, et al. Orthostatic hypotension is associated with nocturnal change in systolic blood pressure. Am J Hypertens 2012;25:159-164.
7. Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 2003;42:136-142.
8. Horowitz DR, Kaufmann H. Autoregulatory cerebral vasodilation occurs during orthostatic hypotension in patients with primary autonomic failure. Clin Auton Res 2001;11:363-367.
9. Maule S, Papotti G, Naso D, Magnino C, Testa E, Veglio F. Orthostatic hypotension: evaluation and treatment. Cardiovasc Hematol Disord Drug Targets 2007;7:63-70.
10. Ziegler MG, Lake CR, Kopin IJ. The sympatheticnervous-system defect in primary orthostatic hypotension. N Engl J Med 1977;296:293-297.
11. Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation 2009; 119:139-146.
12. Novak V, Novak P, Spies JM, Low PA. Autoregulation of cerebral blood flow in orthostatic hypotension. Stroke 1998;29:104-111.
13. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008;7:451-458.
14. Mathias CJ, Kimber JR. Postural hypotension: causes, clinical features, investigation, and management. Annu Rev Med 1999;50:317-336.
15. Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 1988;38:951-956.
16. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993;95:38-48.
17. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997;277:1046-1051.
18. Wright RA, Kaufmann HC, Perera R, et al. A doubleblind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998;51:120-124.
19. Biaggioni I, Robertson D. Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency. Lancet 1987;2:1170-1172.
20. Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threodihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 1999;53:2151-2157.
21. Mathias CJ, Senard JM, Braune S, et al. L-threodihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001;11:235-242.
22. Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003;108:724-728.
23. Goldstein DS, Holmes C, Kaufmann H, Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 2004;14:363-368.
24. Esler M. An explanation of the unexpected efficacy of L-DOPS in pure autonomic failure. Clin Auton Res 2004;14:356-357.
25. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res 2012;22:79-90.
26. Granger JP, Alexander BT, Llinas M. Mechanisms of pressure natriuresis. Curr Hypertens Rep 2002;4:152-159.
27. Lipsitz LA, Ryan SM, Parker JA, Freeman R, Wei JY, Goldberger AL. Hemodynamic and autonomic nervous system responses to mixed meal ingestion in healthy young and old subjects and dysautonomic patients with postprandial hypotension. Circulation 1993;87:391-400.
28. Shannon JR, Diedrich A, Biaggioni I, et al. Water drinking as a treatment for orthostatic syndromes. Am J Med 2002; 112:355-360.
29. Berne RM, Winn HR, Rubio R. The local regulation of cerebral blood flow. Prog Cardiovasc Dis 1981;24:243-260.
30. Aaslid R, Lindegaard KF, Sorteberg W, Nornes H. Cerebral autoregulation dynamics in humans. Stroke 1989;20:45-52.
31. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry: enrichment strategies for clinical trials to support approval of human drugs and biological products. Draft guidance, December 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/ Guidances/UCM332181.pdf. Accessed December 6, 2013.